Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed)
ID: 357625Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357625

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-157.html
Timeline
    Description

    The National Institutes of Health (NIH), through its National Center for Advancing Translational Sciences (NCATS), has announced the Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) funding opportunity. This initiative aims to support the development of innovative technologies that address barriers in therapeutic development, specifically targeting high-risk, high-reward projects that are in the early stages of proof-of-concept. The program is particularly significant as it seeks to enhance the efficiency of the therapeutic development pipeline, ultimately leading to faster delivery of treatments to patients. Grants of up to $275,000 are available over a two-year period, with applications accepted starting May 19, 2025, and a submission deadline of June 19, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-157-Full-Announcement.html
    PAR-25-157.html
    The National Institutes of Health (NIH), through its National Center for Advancing Translational Sciences (NCATS), has announced the Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) funding opportunity. The objective is to support innovative technology development that addresses bottlenecks in therapeutic development. Applications are sought for groundbreaking studies that have high-risk, high-reward potential, with an emphasis on early-stage, proof-of-concept projects. The program offers grants up to $275,000 over two years, specifically excluding clinical trials. Applicants, ranging from higher education institutions to nonprofit organizations, are required to adhere to specific regulations and application processes. Key components of the application include a feasibility analysis, validation plan, and future development strategy. The review process assesses the significance, innovation, and rigor of proposed technologies, focusing on their potential impact on the therapeutic development timeline. The funding opportunity is open for submissions starting May 19, 2025, with a maximum project duration of two years. This initiative emphasizes NIH's commitment to advancing translational science to accelerate the delivery of effective treatments to patients.
    Similar Opportunities
    Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Advancing Translational Sciences (NCATS), has announced the Awards Supporting Cutting-Edge Technologies for Translational Science (ASCETTS) funding opportunity. This grant program aims to support early-stage, high-risk exploratory research focused on developing innovative technologies that address barriers in therapeutic development, rather than targeting specific diseases or clinical trials. The initiative is designed to expedite the discovery and delivery of treatments, diagnostics, and devices to patients by fostering innovative research that can attract industry collaboration and additional funding. Eligible applicants may request up to $275,000 in direct costs over a maximum project period of two years, with applications due by June 19, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the detailed announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-177.html.
    Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through its National Center for Advancing Translational Sciences (NCATS), has announced a funding opportunity for the Limited Competition Small Grant Program (R03), aimed at supporting Clinical and Translational Science Award (CTSA) Program KL2/K12 scholars and diversity supplement recipients. This program is designed to facilitate the transition of these scholars to independent research careers by funding small, self-contained research projects that can be conducted quickly and with limited resources, ultimately addressing inefficiencies in translational science. Grants of up to $50,000 per year are available for projects lasting up to two years, with a submission deadline of January 17, 2025, and an anticipated award cycle beginning in February 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), aimed at supporting advanced pre-clinical research in nanotechnology-based cancer diagnostics and therapeutics. This initiative encourages innovative projects that utilize nanoparticle formulations or nano-devices to address significant clinical objectives in cancer treatment, with a focus on enhancing treatment efficacy through combination therapies and immunotherapy. Funding is available up to $475,000 annually for a maximum of four years, with applications accepted from eligible institutions including higher education entities, nonprofits, and government organizations. Interested applicants should refer to the detailed application process outlined on Grants.gov and the NIH ASSIST system, with key deadlines spanning from April 2025 to November 2027. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program, designated as R03 Clinical Trial Optional. This funding opportunity aims to support KL2/K12 scholars and recipients of diversity and re-entry supplements in their transition to independent research roles by funding small, innovative, self-contained projects in translational science, with a maximum budget of $50,000 per year over a two-year period. The initiative is designed to enhance the capabilities of emerging researchers in addressing inefficiencies in translating research into clinical applications, engaging underrepresented populations, and improving data accessibility through innovative technologies. Applications will be accepted starting January 19, 2024, with multiple deadlines leading up to October 20, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    CCRP Initiative: NIH Countermeasures Against Chemical Threats (CounterACT) Translational Exploratory/Developmental Research Projects (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity under the CCRP Initiative for Countermeasures Against Chemical Threats (CounterACT), aimed at supporting translational exploratory/developmental research projects that advance novel medical countermeasures (MCMs) for serious health impacts resulting from acute exposure to toxic chemical threats. The initiative specifically seeks projects that develop or repurpose existing FDA-approved products as potential treatments, generating preliminary data necessary for broader NIH support, while excluding basic research or environmental decontamination technologies. This funding opportunity has a ceiling of $275,000 over a two-year period, with applications due by May 30, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Limited Competition funding opportunity titled the Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3), aimed at enhancing translational research through collaborative efforts among multiple medical research institutions. This initiative seeks to support the development, implementation, and dissemination of innovative solutions that address urgent public health needs and promote health equity, requiring applicants to include at least three eligible organizations to foster interdisciplinary partnerships. Eligible projects can receive funding of up to $650,000 annually for a total duration of up to five years, with applications due by October 19, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-25-296.html.
    Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled “Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed),” aimed at supporting exploratory research for innovative biomedical technologies. This initiative focuses on high-risk projects that have not yet established feasibility, specifically targeting the development of tools such as laboratory instruments, algorithms, and chemical reagents, while excluding applications that address specific biological questions or present existing proof of concept data. Eligible applicants can request funding of up to $275,000 over two years, with a maximum of $200,000 in any single year, and applications are due by May 7, 2025. For further details, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or refer to the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-126.html.
    Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards (RC2 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Limited Competition: High Impact Specialized Innovation Programs in Clinical and Translational Science for UM1 CTSA Hub Awards." This initiative aims to support the development and demonstration of innovative resources and capabilities within Clinical and Translational Science Awards (CTSA) Program hubs, specifically targeting critical gaps and roadblocks in clinical research. Successful applicants, who must be active UM1 CTSA award recipients, will propose projects lasting up to five years with an annual budget cap of $500,000, emphasizing collaboration and innovation in health research. Interested parties should note that the application deadline is September 14, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)" aimed at supporting innovative preclinical and early-phase clinical research in cancer diagnosis, treatment, and prevention. This grant, with a funding ceiling of $275,000 over two years, encourages exploratory studies that may involve significant risk but have the potential to lead to breakthroughs in cancer research, particularly for underserved populations. Applications will be evaluated based on their significance, innovation, and rigor, with key deadlines for submission set for January 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Notice of Intent to Re-issue PAR-22-167 - Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to re-issue the Notice of Funding Opportunity Announcement (PAR-22-167) for the Clinical and Translational Science Award (CTSA) Program, specifically the Collaborative and Innovative Acceleration Award (UG3/UH3 Clinical Trial Optional). This funding opportunity aims to foster meaningful collaborations and innovative projects in clinical and translational science, with no cost-sharing or matching requirements for eligible applicants, which include for-profit organizations. The estimated total program funding is $5 million, with an award ceiling of $650,000, and the NOFO is expected to be published in Fall 2024, with applications due in Winter 2025. Interested parties should prepare for the anticipated timeline, as the estimated project start date is December 1, 2025, and further details can be found on the CCIA webpage.